Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026
Rhea-AI Summary
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on oral small molecule degrader medicines for immunological diseases, plans to report its second quarter 2026 financial results on August 5, 2026. The company will host a video conference call and webcast at 8:30 a.m. ET on the same day. Investors can access the live video call and livestreamed webcast by registering through a provided link or by visiting the “News and Events” page in the Investors section of Kymera Therapeutics’ website. A replay of the webcast will be archived and made available after the event.
Positive
- None.
Negative
- None.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 23 | Earnings scheduling | Neutral | -1.8% | Scheduled first-quarter 2026 financial results and an 8:30 a.m. ET webcast. |
| Feb 19 | Earnings scheduling | Neutral | +1.6% | Scheduled fourth-quarter and full-year 2025 financial results with an 8:30 a.m. ET webcast. |
| Dec 5 | Clinical results notice | Positive | +41.5% | Scheduled topline BroADen Phase 1b atopic dermatitis trial results for December 8. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Tag-specific earnings-date announcements produced mixed reactions, while the largest positive move followed a clinical-results scheduling notice.
Key Terms
small molecule degrader technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report second quarter 2026 financial results on August 5, 2026. The Company will host a video conference call and webcast at 8:30 a.m. ET that day.
To join the video call or view the livestreamed webcast, please register via this link, or visit “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. A replay of the webcast will be archived and available following the event.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.
Investor Contact:
Justine Koenigsberg
investors@kymeratx.com
857-285-5300
Media Contact:
Matthew Henson
media@kymeratx.com
857-285-5300
